Abstract
The optogenetics approach uses a combination of genetic and optical methods to initiate and control functions in specific cells of biological tissues. Since the high-speed control of neuronal activity by irradiating channelrhodopsin-2 with blue light was reported in 2005, tremendous advancement and application of optogenetics in the field of neuroscience, such as in studies that associate neuronal activity with behaviors, have been initiated. Optogenetics is not only used as a research tool, but is also started to apply in the diagnosis of a disease or as therapy in various studies. Here, we summarize reports on therapy using a typical photoreceptor used in optogenetics, channelrhodopsin-2.
Keywords: Optogenetics, Channnelrhodopsin -2, Gene therapy, Neuroscience, Cardiac resynchronization, Insulin, diabetes.
Current Gene Therapy
Title:Application of Optogenetics in Gene Therapy
Volume: 18 Issue: 1
Author(s): Toshihiro Kushibiki *Miya Ishihara
Affiliation:
- Department of Medical Engineering, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama,Japan
Keywords: Optogenetics, Channnelrhodopsin -2, Gene therapy, Neuroscience, Cardiac resynchronization, Insulin, diabetes.
Abstract: The optogenetics approach uses a combination of genetic and optical methods to initiate and control functions in specific cells of biological tissues. Since the high-speed control of neuronal activity by irradiating channelrhodopsin-2 with blue light was reported in 2005, tremendous advancement and application of optogenetics in the field of neuroscience, such as in studies that associate neuronal activity with behaviors, have been initiated. Optogenetics is not only used as a research tool, but is also started to apply in the diagnosis of a disease or as therapy in various studies. Here, we summarize reports on therapy using a typical photoreceptor used in optogenetics, channelrhodopsin-2.
Export Options
About this article
Cite this article as:
Kushibiki Toshihiro *, Ishihara Miya , Application of Optogenetics in Gene Therapy, Current Gene Therapy 2018; 18 (1) . https://dx.doi.org/10.2174/1566523218666180302163814
DOI https://dx.doi.org/10.2174/1566523218666180302163814 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stability and Biological Activity of Human Intestinal Trefoil Factor Produced by Pichia pastoris
Protein & Peptide Letters Different Types of Cell Death in Organismal Aging and Longevity: State of the Art and Possible Systems Biology Approach
Current Pharmaceutical Design microRNAs and Esophageal Cancer - Implications for Pathogenesis and Therapy
Current Pharmaceutical Design VaD - An Integrated Framework for Cognitive Rehabilitation
CNS & Neurological Disorders - Drug Targets Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Roles of Glutamate and Glutamine Transport in Ammonia Neurotoxicity: State of the Art and Question Marks
Endocrine, Metabolic & Immune Disorders - Drug Targets Canagliflozin : A New Hope in the Antidiabetic Armamentarium
Recent Patents on Cardiovascular Drug Discovery Attenuation of Diabetes-induced Cardiac and Subcellular Defects by Sulphur-containing Amino Acids
Current Medicinal Chemistry Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
Current Rheumatology Reviews AMPK in Neurodegenerative Diseases: Implications and Therapeutic Perspectives
Current Drug Targets Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Recent Patents on Biotechnology Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science VEGF and Colon Cancer Growth Beyond Angiogenesis: Does VEGF Directly Mediate Colon Cancer Growth Via a Non-angiogenic Mechanism?
Current Pharmaceutical Design The CNS Melanocortin System: A Biological Weapon Against the Threat of Obesity
Current Medicinal Chemistry - Central Nervous System Agents Regulation of Insulin Synthesis and Secretion and Pancreatic Beta-Cell Dysfunction in Diabetes
Current Diabetes Reviews Vacuolar H+-ATPase Signaling Pathway in Cancer
Current Protein & Peptide Science Modified Hummel-Dreyer Method and Molecular Modeling Studies Identified Nicotinic Acid Analogues as Carbonic Anhydrase III Ligands
Letters in Drug Design & Discovery Peptides as Carrier for Tumor Diagnosis and Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Biology and Therapeutic Applications of Peroxisome Proliferator- Activated Receptors
Current Topics in Medicinal Chemistry